BOTOX 50 UNIT — DIN 02531577
ONABOTULINUMTOXINA : 50 UNIT · ABBVIE CORPORATION · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is BOTOX?
BOTOX 50 UNIT contains ONABOTULINUMTOXINA : 50 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02531577, held by ABBVIE CORPORATION, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 20-Jun-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BOTOX used for?
BOTOX® (onabotulinumtoxinA for injection) is indicated for the treatment of blepharospasm associated with dystonia, strabismus, to reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults, in the management of focal spasticity (upper limb spasticity in adults, lower limb spasticity in adults, upper and/or lower limb spasticity in pediatric patients two years of age or older), for the treatment of hyperhidrosis of the axilla in patients 18 years of age or older, for the prophylaxis of headaches in adults with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer), for the treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from neurogenic bladder associated with multiple sclerosis or sub cervical spinal cord injury in adults who had an inadequate response to or are intolerant of anticholinergic medications, and for the treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adult patients who have an inadequate response to or are intolerant of anticholinergic medication.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Botulinum Toxin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Botulinum Toxin, across 16 DINs, of which 12 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ABBVIE CORPORATION | 5 | 4 | BOTOX, BOTOX COSMETIC | Sourceable in Canada |
| MERZ PHARMACEUTICALS GMBH | 4 | 3 | XEOMIN, XEOMIN COSMETIC | Sourceable in Canada |
| IPSEN BIOPHARMACEUTICALS CANADA INC | 2 | 2 | DYSPORT THERAPEUTIC | Sourceable in Canada |
| HUGEL CANADA INC. | 2 | 1 | LETYBO | Sourceable in Canada |
| EVOLUS INCORPORATED | 1 | 1 | NUCEIVA | Sourceable in Canada |
| IPSEN BIOPHARMACEUTICALS CANADA INC SUITE 500 5050 Satellite Drive Mississauga Ontario Canada L4W 0G1 | 1 | 1 | DYSPORT AESTHETIC | Sourceable in Canada |
| SOLSTICE NEUROSCIENCES, LLC, A SUBSIDIARY OF MDD US OPERATIONS, LLC | 1 | 0 | MYOBLOC | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 UNIT |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | 50, 100 and 200 Allergan units per vial |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Botulinum Toxin |
|---|---|
| ATC code | M03AX01 |
| AHFS class | 28:36.16 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02531577 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2531577 |
| Brand name | BOTOX |
| Generic / active ingredient | ONABOTULINUMTOXINA : 50 UNIT |
| Market authorization holder | ABBVIE CORPORATION |
| Health Canada schedule | Schedule D |
| ATC code | M03AX01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M03AX |
| Current status | MARKETED |
| Status date | 20-Jun-2023 |
| Original market date | 2023-04-28 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
12 of 16 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BOTOX | 200 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | 02531585 |
| BOTOX | 100 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | 01981501 |
| BOTOX COSMETIC | 100 UNIT | POWDER FOR SOLUTION | ABBVIE CORPORATION | MARKETED | 02243721 |
| DYSPORT AESTHETIC | Strength | Powder For Solution | IPSEN BIOPHARMACEUTICALS CANADA INC SUITE 500 5050 Satellite Drive Mississauga Ontario Canada L4W 0G1 | MARKETED | 02387735 |
| DYSPORT THERAPEUTIC | 500 UNIT | POWDER FOR SOLUTION | IPSEN BIOPHARMACEUTICALS CANADA INC | MARKETED | 02456117 |
| DYSPORT THERAPEUTIC | 300 UNIT | POWDER FOR SOLUTION | IPSEN BIOPHARMACEUTICALS CANADA INC | MARKETED | 02460203 |
| LETYBO | 100 UNIT | POWDER FOR SOLUTION | HUGEL CANADA INC. | MARKETED | 02528142 |
| NUCEIVA | 100 UNIT | POWDER FOR SOLUTION | EVOLUS INCORPORATED | MARKETED | 02480158 |
| XEOMIN | 100 UNIT | POWDER FOR SOLUTION | MERZ PHARMACEUTICALS GMBH | MARKETED | 02324032 |
| XEOMIN | 50 UNIT | POWDER FOR SOLUTION | MERZ PHARMACEUTICALS GMBH | MARKETED | 02371081 |
2 · Same class — other molecules in ATC M03AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Botulinum Toxin | BOTOX · BOTOX COSMETIC · DYSPORT AESTHETIC · DYSPORT THERAPEUTIC · +5 more | 16 | 12 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M03AC | Atracurium · Cisatracurium · Doxacurium Chloride · Gallamine · Mivacurium Chloride · +3 more | 44 | 7 |
| M03AB | Suxamethonium | 9 | 3 |
| M03AA | Dimethyltubocurarine · Tubocurarine | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.